As scientists race to develop a vaccine and novel therapies to combat the COVID-19 pandemic, investors are looking into the investment return in biotech and pharmaceutical companies. In recognition of the high demand for equity finance in the biomedical industry, HKEx incorporated three new chapters into the Listing Rules on 30 April 2018.  The new policy aims to allow listing of pre-revenue biotech companies on the HKEx Main Board. In addition, a new secondary listing route has been introduced for innovative companies listed on the NYSE, NASDAQ and LSE.

Our speaker will walk you through the new listing rules in Chapter 18A and the respective guidance letters issued by HKEx. The course will give you a good understanding of the regulatory framework of biotech company listings.